PELP-1 promotes adverse endocrine therapy response in ER plus breast cancer

被引：0
|
作者：
Rees, Michael [1 ]
Smith, Chris [2 ]
Barrett-Lee, Peter [1 ]
Hiscox, Stephen [2 ]
机构：
[1] Velindre Canc Ctr, Cardiff, S Glam, Wales
[2] Cardiff Univ, Cardiff, S Glam, Wales
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-2884
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2884
引用
收藏
页数：2
相关论文
共 50 条
  • [21] The impact of neoadjuvant endocrine therapy (NET) in ER plus breast cancer tumor microenvironment and metastasis
    Chondronikola, Anastasia Aristoteleia
    Anastasiadou, Dimitra
    Zintiridou, Aliona
    Duran, Camille L.
    Barth, Nicole
    Karadal-Ferrena, Burcu
    Pereira-Zambalde, Erika
    Ariyan, Lina
    Shukla, Suryansh
    Karagiannis, George S.
    Entenberg, David
    Condeelis, John S.
    Oktay, Maja H.
    CANCER RESEARCH, 2024, 84 (22)
  • [22] Lessons in precision oncology from neoadjuvant endocrine therapy trials in ER plus breast cancer
    Ellis, Matthew J.
    BREAST, 2017, 34 : S104 - S107
  • [23] Significance of PELP1 in ER-Negative Breast Cancer Metastasis
    Roy, Sudipa
    Chakravarty, Dimple
    Cortez, Valerie
    De Mukhopadhyay, Keya
    Bandyopadhyay, Abhik
    Ahn, Jung-Mo
    Raj, Ganesh V.
    Tekmal, Rajeshwar R.
    Sun, LuZhe
    Vadlamudi, Ratna K.
    MOLECULAR CANCER RESEARCH, 2012, 10 (01) : 25 - 33
  • [24] Estrogens Correlate with PELP1 Expression in ER Positive Breast Cancer
    Flageng, Marianne Hauglid
    Knappskog, Stian
    Gjerde, Jennifer
    Lonning, Per Eystein
    Mellgren, Gunnar
    PLOS ONE, 2015, 10 (08):
  • [25] Impact of SNPs in ERα corepressor SMRT on breast cancer risk and response to endocrine therapy
    Hartmaier, R. J.
    Skaar, T. C.
    Rae, J.
    Wang, J.
    Li, L.
    Oesterreich, S.
    CANCER RESEARCH, 2009, 69 (02) : 118S - 119S
  • [26] Riluzole Suppresses Growth and Enhances Response to Endocrine Therapy in ER+ Breast Cancer
    Olukoya, Ayodeji O.
    Stires, Hillary
    Bahnassy, Shaymaa
    Persaud, Sonali
    Guerra, Yanira
    Ranjit, Suman
    Ma, Shihong
    Cruz, M. Idalia
    Benitez, Carlos
    Rozeboom, Aaron M.
    Ceuleers, Hannah
    Berry, Deborah L.
    Jacobsen, Britta M.
    Raj, Ganesh V.
    Riggins, Rebecca B.
    JOURNAL OF THE ENDOCRINE SOCIETY, 2023, 7 (10)
  • [27] Protein tyrosine kinase 6 (PTK6) promotes survival of endocrine therapy-resistant ER plus breast cancer cells
    Irie, Hy
    Park, S. H.
    Katsyv, I.
    Zhang, W.
    Nayak, A.
    CANCER RESEARCH, 2017, 77
  • [28] Ribociclib plus Endocrine Therapy in Early Breast Cancer
    Tu, Hengjia
    Zhang, Yuzhuo
    You, Zhixuan
    Li, Qian
    Cai, Yuanxuan
    Li, Jie
    Tannock, Ian F.
    Meirson, Tomer
    Fojo, Antonio
    Slamon, Dennis
    Yardley, Denise A.
    Hortobagyi, Gabriel
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (23): : 2219 - 2222
  • [29] Ribociclib plus Endocrine Therapy in Early Breast Cancer
    Slamon, Dennis
    Lipatov, Oleg
    Nowecki, Zbigniew
    McAndrew, Nicholas
    Kukielka-Budny, Bozena
    Stroyakovskiy, Daniil
    Yardley, Denise A.
    Huang, Chiun-Sheng
    Fasching, Peter A.
    Crown, John
    Bardia, Aditya
    Chia, Stephen
    Im, Seock-Ah
    Ruiz-Borrego, Manuel
    Loi, Sherene
    Xu, Binghe
    Hurvitz, Sara
    Barrios, Carlos
    Untch, Michael
    Moroose, Rebecca
    Visco, Frances
    Afenjar, Karen
    Fresco, Rodrigo
    Severin, Irene
    Ji, Yan
    Ghaznawi, Farhat
    Li, Zheng
    Zarate, Juan P.
    Chakravartty, Arunava
    Taran, Tetiana
    Hortobagyi, Gabriel
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (12): : 1080 - 1091
  • [30] The role of PELP1-TFAP2C crosstalk in mediating endocrine-therapy-resistance in breast cancer
    Liu, Junhao
    Viswanadhapalli, Suryavathi
    Li, Mengxing
    Pratap, Uday P.
    Luo, Yiliao
    Altwegg, Kristin A.
    Li, Xiaonan
    Sareddy, Gangadhara R.
    Tekmal, Rajeshwar R.
    Vadlamudi, Ratna K.
    CANCER RESEARCH, 2020, 80 (04)
12345